Galenagen, LLC received the patent to remotely monitor Parkinson’s Disease by the United States Patent and Trademark Office (USPTO). Galenagen’s patent is directed to methods of employing remote data gathering and monitoring for diagnosis, staging and treatment of Parkinson’s Disease, movement and neurological disorders and chronic pain. The technology will help facilitate early Parkinson’s staging and ongoing monitoring of a patient’s condition.
Dr. Joan Fallon, CEO and Founder, Curemark said: “Given the devastating impact of Parkinson’s on patients, their families and the healthcare system, improving access to data that can inform physicians should improve care. This should be a more equitable way to receive care and have a patient’s condition monitored for changes especially for those who live in rural areas or find travel impacted by the disease.”